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Abstract
Background: Recent clinical trials of VEGF inhibitors have shown promise in the treatment of recurrent glioblastomas (GBM).
However, the survival benefit is usually short-lived as tumors escape anti-VEGF therapies. Here we tested the hypothesis
that Platelet Derived Growth Factor-C (PDGF-C), an isoform of the PDGF family, affects GBM progression independent of
VEGF pathway and hinders anti-VEGF therapy.
Principal Findings: We first showed that PDGF-C is present in human GBMs. Then, we overexpressed or downregulated
PDGF-C in a human GBM cell line, U87MG, and grew them in cranial windows in nude mice to assess vessel structure and
function using intravital microscopy. PDGF-C overexpressing tumors had smaller vessel diameters and lower vascular
permeability compared to the parental or siRNA-transfected tumors. Furthermore, vessels in PDGF-C overexpressing tumors
had more extensive coverage with NG2 positive perivascular cells and a thicker collagen IV basement membrane than the
controls. Treatment with DC101, an anti-VEGFR-2 antibody, induced decreases in vessel density in the parental tumors, but
had no effect on the PDGF-C overexpressing tumors.
Conclusion: These results suggest that PDGF-C plays an important role in glioma vessel maturation and stabilization, and
that it can attenuate the response to anti-VEGF therapy, potentially contributing to escape from vascular normalization.
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Introduction
Glioblastoma Multiforme (GBM) is a uniformly fatal tumor
afflicting approximately 9,000 persons each year in the United
States, and there is currently no efficacious therapy. Standard
treatment is maximal resection, combined daily temozolomide and
radiation (chemoradiation) followed by 6 monthly cycles of post-
radiation temozolomide alone. Unfortunately, survival after
recurrence is only a few months [1]. Anti-VEGF treatment of
recurrent tumors has shown some promise, but these tumors
invariably escape VEGF-blockade [2,3,4]. Thus novel targets are
desperately needed to guide the development of more effective,
innovative therapeutic approaches.
Platelet-derived growth factors (PDGF) are a pleiotropic family
of peptides that signal through cell surface, tyrosine kinase
receptors (PDGFR) and stimulate cellular functions including
growth, proliferation and differentiation [5]. The PDGF family
was initially discovered as a mitogen in human serum, localized in
the alpha-granules of platelets [6]. The biological role of PDGF
signaling in solid tumors can vary from autocrine stimulation of
cancer cell growth [7,8] to subtler paracrine interactions involving
adjacent stroma [9,10,11], and vasculature [8,12].
PDGF-dependent mitogenic pathways have been implicated in
the pathogenesis of astrocytomas [13], as both PDGF A and B
proteins are expressed in malignant astrocytomas. Less is known
about the recently-identified PDGF-C and –D isoforms
[14,15,16], but PDGF-C mRNA has been detected in several
glioma cell lines [17], and it is evidently able to induce de-
differentiation of astrocytes [18]. In addition, PDGF-C has been
reported to induce angiogenic activity indirectly, via upregulation
of VEGF [16,19], and directly, via activation of PDGF-Ra and
Ra2Rb receptors [20]. These observations, along with the fact
that PDGF-Ra and -Rb are expressed in astrocytomas [21] and
glioma endothelial cells [22] point to PDGF-C as a potentially
important mediator of brain tumor progression. In this study, we
over- and under-expressed PDGF-C in a human glioma line
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5123U87MG to assess the role of PDGF-C in glioma angiogenesis and
in anti-VEGFR-2-induced vessel normalization.
Materials and Methods
Ethics Statement
All animal experiments performed in this study were conducted
in compliance with the guidelines of the Office of Live Animal
Research at Massachusetts General Hospital.
PDGF-C over expression
To overexpress PDGF-C, the full-length cDNA was cloned into
a peak12 vector driven by the EF1-a promoter (obtained from Dr.
Brian Seed, Massachusetts General Hospital, Boston, MA). This
expression vector was stably transfected into U87MG cells using
LipofectAMINE 2000 (Invitrogen, Carlsbad, CA) according to the
manufacturer’s protocol. Transfected cells were selected with
0.5 mg/ml puromycin. Because of the lack of the necessary
activating enzymes contained in normal fetal calf serum, plasmin
digestion was used to demonstrate the proteolytic removal of the
CUB domain confirming that the PDGF-C protein would be
functional.
RNA interference
PDGF-C down regulation was achieved using the pSilencer
hygro (Ambion, Austin, TX) expression vector. The sequences for
the PDGF-C shRNAi were taken from Genbank accession
no. NM_016205. The coding sequences for shRNAi started with
AA and were chosen so that there was no significant sequence
homology with other genes, especially other PDGF family genes,
assessed via Basic Local Alignment Search Tool (BLAST) analysis
(http://blast.ncbi.nlm.nih.gov/blast). Hairpin shRNAi-encoding
oligonucleotides were allowed to anneal and then ligate into the
vector according to the manufacturer’s protocol. Bacteria were
transformed with the vector and screened using a restriction digest
to ensure plasmid uptake. The plasmid was amplified and
transfected into U87MG cells using LipofectAMINE 2000.
Transfected cells were selected using hygromycin and clones were
screened using western blot analysis to demonstrate lower protein
levels due to RNA interference. ‘‘Scrambled’’ shRNA was used as
the mock transfection control.
Animal model and treatment
Cranial windows were implanted into 8–10 week old male
SCID mice as previously described [23,24]. After one week, a
single cell suspension (200,000 cells) of U87MG, U87-C (PDGF-C
transfected variant) or U87si (shRNAi-transfected variant) was
implanted under the window into the cerebral cortex at a depth of
approximately 0.4 mm. Treatment with the anti-VEGFR2
antibody DC101 (ImClone System Inc., New York, NY) was
started as soon as the tumors reached a mean diameter of 2.0 to
2.5 mm, and this was designated day 0. DC101 was administered
i.p. (40 mg/kg) every third day for a maximum of three doses (day
0, 3, and 6); a control group with size-matched tumors received
non-specific rat IgG at 40 mg/kg on a similar schedule.
Multiphoton Laser Scanning Microscopy (MPLSM)
Angiography
In vivo MPLSM angiography of glioblastoma vessels was
performed as described previously [24]. For each tumor, four
adjacent images were obtained through the cranial window at day
0 (before treatment), and the same regions were revisited and
recorded at day 2, 5, and 8. For each region, 41 images spaced
5 microns apart were collected in the z direction, producing
,51265126200 mm volume stacks. A maximum intensity
projection of images 16 to 41 was created, representing the region
from 75 mm to 200 mm under the brain surface. Image analysis
was performed as described previously [25].
Vessel wall analysis
Brains of tumor-bearing mice were harvested three weeks (65
days) after implantation when tumors reached a mean diameter of
2.5 (61) mm. Perfused vessels, were labeled by injection of
biotinylated Lycopersicon Esculentum lectin and the tissue was
fixed by perfusion of 4% paraformaldehyde [26]. Brains were
embedded in OCT and stored at 280uC. Frozen sections (10 mm)
were incubated with a streptavidin-conjugated Alexa 488 to
visualize the lectin (Molecular Probes Inc., Eugene, OR) and
stained with one of the following Chemicon primary antibodies:
rabbit anti-Collagen IV (1:2000; AB756), rabbit anti-NG2 (1:1000;
AB5320), or rabbit anti-Desmin (1:200). For quantification, five
well-vascularized regions per section were randomly selected and
imaged using identical microscope settings. Pericyte coverage in
control tumors and PDGF-C overexpressors was assessed by the
intensity profile of pericyte staining near the vascular endothelium:
the fraction of NG2- or desmin- positive pixels was analyzed at
various distances from the vessel wall, and the average signal for
each animal (based on 5 areas) is plotted.
Cell Proliferation Assay
Cell proliferation was measured using Cell Titer 96H Aqueous
One Solution obtained from Promega (Madison, Wisconsin). Cells
were washed with PBS, trypsinized, and counted using the trypan
blue exclusion assay. Cells were seeded at different densities in a 96
well plate and allowed to proliferate for 18 hours. The media was
then changed and 20 ml of Cell Titer MTS solution was added to
each well. After two additional hours, absorbance was read at
490 nm on a plate reader. Each seeding density was run in
triplicate and the experiment was repeated three times.
Cell migration Assay
Calcein AM (Molecular Probe, Eugene, OR) –labeled cells were
seeded in laminin pre-coated Fluoroblock
TM filter wells (Becton
Dickinson, Palo Alto, CA). 6610
4 cells suspended in 300 ml media
were placed into each well insert. Image analysis quantified the
rate of cell migration through the 8 mm pores to the bottom of the
filter, based on images acquired from the bottom of each well 1, 2,
3, 6, 12, 24 hours after seeding.
Receptor and transcript analysis
Wild-type and stably-transfected U87 cells were cultured in
serum-free medium overnight. Media were collected and protein
concentration determined. In total, 35 mg protein was precipitat-
ed using ice-cold 10% trichloroacetic acid (TCA). Precipitated
proteins were washed several times with 80% ethanol and then
subjected to SDS–PAGE using 12% polyacrylamide gels (BioRad)
under reducing conditions. Immunoblotting was performed using
PDGF-C (1:1,000, R&D Systems Minneapolis, MN), PDGFRa
(1:1,000, Cell Signaling, Beverly, MA) and phospho-PDGFRa
(1:1,000, Cell Signaling, Beverly, MA) antibodies. Bound antibod-
ies were detected using Enhanced Chemiluminiscence Plus
reagent (ECL+, Amersham).
Plasmin Digestion
Conditioned Media samples were digested with 0.5–1 units per
ml of plasmin in 40 mM Tris-HCl, 2 mM CaCl2, 2 mM MgCl2,
PDGF-C Sin Brain Tumors
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analysis using 15% polyacrilamide gels demonstrated removal of
the PDGF-C CUB domain; this removal is essential for binding of
PDGF-C to its receptors.
Vessel Network Analysis
Vessel networks were quantified as described previously [25]. In
summary, the tracing algorithm begins by extracting a set of
candidate seeds over a sparse grid. Then, a super-ellipsoid model is
fit at each seed. If a vessel is detected, tracing proceeds in the
forward/reverse directions using the locally estimated pose.
During tracing, the model is restricted to moving in the normal
plane perpendicular to the medial axis of the best-fit super-
ellipsoid. Tracing continues until the trace hits the boundary,
another vessel, or the likelihood ratio falls below a predetermined
threshold. The tracing results provide a vectorized backbone of the
vascular bed including topological information such as branch
points and the number of vessel segments.
Microvascular Permeability Measurement
Mice were first injected with a bolus (0.1 ml) of 10 mg/ml
fluorescein-labeled Dextran (2 M MW; Sigma) i.v., and angio-
Figure 1. PDGF-C expression in human gliomas – autocrine & paracrine signaling. A: Expression of PDGF-C in human samples of gliomas.
27 samples of Grade IV glioma (Tissue Microarrays, kind gift from Dr. David Louis, MGH) were screened for expression of PDGF-C using
immunohistochemistry (PDGF-C monoclonal antibody from R&D, used at 1/100). 23 out of 27 specimens expressed PDGF-C in tumor cells and/or in
the peri-vascular area. Panels I, II and III are 3 different patients; panel IV is normal brain tissue present on the same array. In I and III positive tumor
cells can clearly be identified; positive endothelium is evident in I and II, and perivascular cells also stain in panel II. In all panels, brown color (DAB)
shows positive labeling for PDGF-C while blue (hematoxilin) stains nuclei. B: PDGF-C RNA expression in several common glioma cell lines. We chose
U87 since it has a relatively low level expression compared to other cell lines and is thus amenable to downreglation. C: Lack of autocrine effect of
PDGF-C on U87MG cells. Qt-RTPCR of PDGFRa in U87 cells shows that RNA is present, but there is no protein detectable by Western blot (not shown).
PDGFRb protein expression in parental (U87MG), PDGF-C overexpressor (U87-C), Mock-transfected (M) or ShRNAi cells (si). PDGFRb phosphorylation.
Cells were treated overnight with one of the following: recombinant PDGF-B (rBB, positive control); conditioned medium from cells overexpressing
PDGF-C (CC); fresh DMEM culture medium (DMEM). PDGF-C did not induce phosphorylation above the baseline level. D: Effect of PDGF-C on 10T1/2
myofibroblasts. Panel I, Top: Phosphorylation of PDGFRb. Cells were stimulated overnight with fresh DMEM culture medium (DMEM), recombinant
PDGFBB (rBB; positive control), U87-C conditioned medium (CC), or conditioned medium from mock-transfected cells (M). PDGF-C did not stimulate
this receptor. Bottom: phosphorylation of PDGFRa on 10T1/2 cells in culture. Cells were stimulated overnight with conditioned medium from U87si
(si), U87-CC (CC), mock transfected cells (M), or fresh DMEM culture medium (DMEM). Recombinant PDGFAA was used as a positive control (rAA). The
phosphorylation induced by the mock and U87si media is likely due to PDGF-A produced by these cells. Treatment of 10T1/2 cells with PDGF-C
conditioned medium results in faster migration (Boyden chamber assay; panel II) and proliferation (WST-1 assay; panel III).
doi:10.1371/journal.pone.0005123.g001
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objective lens of an epifluorescence microscope. Thereafter, 1%
tetramethylrhodamine-labeled BSA (Molecular Probes, Eugene,
OR) was injected, and rhodamine fluorescence intensity of the
tumor tissue was measured every 2 min for a total of 20 min by a
photomultiplier (9203B; EMI, Rockaway, NJ). The microvascular
permeability to albumin was then calculated from the change in
intensity as previously described [27].
Statistical analysis
Data are expressed as mean6standard error of the mean. The
principle statistical test was the Mann-Whitney U test; p,0.05 was
considered to be statistically significant.
Results
Human gliomas express significant levels of PDGF-C
To assess whether PDGF-C is expressed in human glioblasto-
mas, we first examined a series of 27 surgical specimens of human
glioblastomas from MGH patients. In 23 of these samples, we
detected PDGF-C in cancer cells but also in endothelial and
perivascular cells (Figure 1A). In contrast, there was no detectable
PDGF-C in normal brain; this suggested that PDGF-C might play
a role in human gliomas.
PDGF-C affects myofibroblasts, but not U87 cells, in
vitro. We then developed PDGF-C over- and under-expressing
glioma cells. After screening five common glioma cell lines (T98G,
HGL21, U87, U373, U138) for expression of PDGF-C (see
Figure 1B), we chose U87MG as the parental line because of its
relatively modest levels of PDGF-C, which made it possible to
effectively down-regulate, as well as over-expressPDGF-C in this line.
Since some gliomas express the PDGF-C receptors PDGFRa
and PDGFRb [4,28] we checked for autocrine signaling in our
U87MG cells. Although PDGFRa protein was undetectable in the
parental or transfected U87MG cells by western blot analysis, RT-
PCR confirmed a low level of expression (Figure 1C). The other
receptor, PDGFRb, was detected by Western blot, but its
expression level was the same in the U87-C, U87-mock or
U87si cell lines. Even in the U87-C cells, which produce high
levels of PDGF-C, there was only a background level of PDGFRb
phosphorylation, indicating a lack of autocrine signaling
(Figure 1C). There was also no significant difference in
proliferation or migration between the parental and transfected
cells in culture. Consequently, PDGF-C did not produce an
autocrine effect on any of the U87 variants.
Angiogenesis array analysis of the three cell types revealed that
overexpression or downregulation of PDGF-C had no effect on
RNA levels of other angiogenic molecules such as VEGFA,
Angiopoietins, IL8 and neuropilin 1. In addition, western blot
analysis confirmed that levels of PDGF-A and PDGF-B, which are
both expressed in U87 cells, were not changed by PDGF-C
transfection.
Figure 2. Blood vessel morphology in brain tumors. A: PDGF-C expression causes a decrease in vessel diameter over 15 days of growth. B: At
day 15 after implantation, the vessel size distribution in the PDGF-C over-expressing tumors resembles that of normal brain, while the siRNA and
parental tumors have distributions shifted to higher diameters, with significant numbers of large-diameter (.25 mm) vessels. C: representative 2-
photon images of the vessel networks.
doi:10.1371/journal.pone.0005123.g002
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and differentiation [29]. To check whether our cells induce
myofibroblast proliferation or migration, we applied conditioned
medium (CM) to 10T1/2 cells, and found that proliferation and
migration rates were significantly increased when the cells were
stimulated with U87-C CM compared to Mock or U87si CM
(Figure 1D).
PDGF-C stabilizes tumor vessels
A hallmark of gliomas is abnormal vascularization. Typically,
blood vessels in these tumors are large, tortuous, leaky, and they
have fewer perivascular cells and abnormal basement membrane
[24,30]. We have shown that anti-angiogenic therapy can
transiently normalize glioma vessels, decreasing vessel densities,
diameters and permeability, and inducing a more normal
basement membrane and wall structure [24,30]. This normaliza-
tion can actually prolong survival by decreasing the edema
associated with the abnormal vasculature [30].
To check whether PDGF-C is involved in vessel abnormalities
or normalization, we grew tumors from single cell suspensions in
the brain parenchyma of immunodeficient mice bearing transpar-
ent cranial windows and performed longitudinal intra-vital
analysis [23]. Fluorescent angiography revealed dramatic differ-
ences in tumor vasculature that varied with the level of PDGF-C
produced by the tumors. By day 15 after implantation, vessels in
PDGF-C overexpressing tumors were more normal, with relatively
small diameters (Figure 2). In contrast, U87si had larger blood
vessels (Figure 2A and 2C). In addition, the distributions of vessel
sizes were quite different; for example, the U87si and parental
tumors had more large-diameter vessels (.25 mm) than the U87-C
tumors (Figure 2B).
PDGF-C also affected vessel function. Permeability analysis [24]
showed that tumor vessels in U87-C tumors were less permeable
than the parental or U87RNAi tumors at both 6 and 15 days after
implantation (Figure 3A). The decreased vessel leakiness likely
contributed to the poor distribution of the fluorescent BSA
throughout the U87-C tumors compared to the parental and
U87RNAi- tumors (Figure 3B). It is also possible, however, that
PDFG-C affected interstitial transport, hindering penetration. The
differences in permeability could not be attributed to differences in
VEGFA levels, as there were no significant differences in VEGF
expression by RT-PCR (either tumor- or host- produced) between
U87-C, U87si and mock-transfected tumors.
Because vessel structure and function can be affected by
association with perivascular cells, we next analyzed coverage of
the tumor vessels by NG2- and desmin-positive pericytes. More of
the U87-C tumor vessels were covered by NG2-positive
perivascular cells (Figure 4A, B), and these cells extended more
than 10 mm away from the vessels (Figure 4D). On the other hand,
PDGF-C did not affect the distribution of desmin-positive
perivascular cells: the parental and U87-C tumors had similar
coverage by these cells, and in both cases, the cells were closely
associated with the endothelium (distance less than ,4 mm;
Figure 4E). This indicates that PDGF-C recruited more
perivascular cells to the vessel wall, and the expression patterns
show that either the recruited cells expressed NG2 predominately,
or else PDGF-C induced expression of NG2 in desmin-positive
cells already close to the wall.
Figure 3. PDGF-C affects the transvascular flux of BSA. A: Effective vascular permeability was measured 6 days and 15 days after tumor
implantation. The vessels in PDGF-C overexpressing tumors have lower permeability both 6 and 15 days following implantation. Normal brain (NB)
vessels are relatively impermeable. B: Delivery of the BSA marker (red) is inhibited by PDGF-C overexpression (Green=CD31).
doi:10.1371/journal.pone.0005123.g003
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PDGF-C were accompanied by differences in the vascular
basement membrane. U87-C tumor vessels had greater coverage
of collagen IV, and the collagen IV layer was thicker, extending
farther from the vessel wall (Figure 4F). These changes in wall
structure likely contributed to the differences in tumor vessel
function.
Overexpression of PDGF-C confers resistance to anti-
VEGF therapy
It has been suggested that increased pericyte fortification can
render vessels insensitive to anti-VEGF therapy [31]. To assess
whether the changes in wall structure induced by PDGF-C affect
the response to anti-VEGF therapy, we treated tumor-bearing
animals with the anti-VEGFR-2 antibody DC101. In our prior
study, this dose and schedule of DC101 induced vessel
normalization and modest tumor regression in U87 tumors [24].
On day zero (just before the initial treatment), the PDGF-C
tumors had lower vessel density compared to the parental tumors
(Figure 5); with treatment, however, the parental tumor vessel
density decreased, while the number of branches in the U87-C
tumor remained virtually unchanged. This suggests that PDGF-C
protects tumor vessels from DC101-induced pruning.
Treatment with DC101 increases PDGF-C expression in
host cells
It has been shown that in murine tumors resistant to anti-VEGF
treatment, tumor associated fibroblasts (TAFs) increase their
production of PDGF-C to sustain angiogenesis [32]. To assess
whether this pathway operates in our system we quantified mRNA
levels for murine PDGF-C in tumor-bearing animals (wild type
U87MG) treated with DC101. Eight days after initiation of the
treatment murine PDGF-C in the tumor extract was significantly
increased (p=0.041) compared to control brain (Figure 6)
confirming that PDGF-C is possibly involved in resistance to
anti-VEGFR2 therapy in brain tumors as well. In contrast murine
VEGF-A, human VEGF-A and PDGF-C did not increase.
Discussion
PDGF-C is evidently involved in many aspects of stromal
dynamics. It has been shown to mediate renal fibrosis [33], to be
Figure 4. Changes in wall structure in response to PDGF-C overexpression. NG2 expression detected by confocal imaging of U87MG (A)
and U87-C (B) tumors using immunohistochemistry on frozen sections of tumors harvested after 3 weeks post-implantation. Red pseudocolor
represents NG2 positive cells, green pseudocolor represents CD31 positive endothelial cells. Panel C shows staining for NG2 (blue), desmin (red) and
CD31 (green) on a 100 mm projection acquired with a confocal microscope. Panels D and E: quantification of NG2 and desmin, respectively. PDGF-C
expression does not affect desmin-positive cell recruitment, but dramatically increases the number of NG2-positive cells around vessels. F: collagen IV
distribution around vessels. The basement membrane is typically thicker than normal in U87MG [24] but U87-C displays an even thicker basement
membrane.
doi:10.1371/journal.pone.0005123.g004
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malignant pleural mesothelioma [35] and to recruit stromal cells
during carcinogenesis in lung [36] and liver [37]. Its role in brain
tumors has been less studied, but its potential importance was
highlighted by studies from Lokker and coworkers, showing a
potential autocrine role of PDGF-C in gliomas [17].
In the current study we established that PDGF-C plays a role in
glioma progression through anti-VEGF therapy. We found that
over expression of this growth factor changes the morphology and
function of the brain vessels, rendering them more stable and less
sensitive to anti-VEGFR-2 inhibition.
We specifically chose U87 as the parental cell line because of its
lack of PDGF-C autocrine signaling (possibly because these cells
express very little PDGFRa); this allowed us to focus on the
paracrine effects on the vasculature. However, a recent survey of
patient archival biopsies showed that 93% of GBMs had
detectable levels of PDGFRa and 37% had detectable PDGFRb
on tumor cells, while 93% and 100% had detectable levels in
blood vessels, respectively [4]. Therefore, future studies should
assess the presence and implications of autocrine signaling in
gliomas, and the potential benefits of inhibitors that also target the
PDGF receptor, such as Cediranib. We expect that the vascular
effects demonstrated here will still exist in tumors with autocrine
PDGF-C signaling, but they might be accompanied by more
aggressive cancer cell proliferation and migration.
Studies of the involvement of PDGF-C in ischemic stroke have
shown that it increases the permeability of the blood brain barrier
by acting on perivascular astrocytes in response to tissue
plasminogen activator [38]. This result conflicts with our decrease
in permeability with PDGF-C expression, and may be due to the
chronic expression of PDGF-C in our tumor model, which
contrasts with the abrupt perturbations caused by strokes in
otherwise healthy brain tissue. In this case tPA activation of the
latent PDGF-C activates PDGFRa/b and increases permeability.
This could be blocked by administration of a PDGFR blocker,
such as, imatinib. In tumor tissue, however, inhibition of PDGFR
has been shown to induce the opposite effect, increasing
permeability, and increasing fluid retention and ascites in cancer
patients [39,40]. These contrary responses are likely due to
differences in the structure of tumor vessels compared to normal
brain vessels.
We propose that, in our system, expression of PDGF-C drives the
recruitment and differentiation of perivascular cells, resulting in
better basement membrane integrity and a more mature, stable
vascular wall with a lower permeability. Indeed, it has been shown
that brain and peripheral nerve pericytes can contribute directly to
vessel wall barrier function via pericyte-pericyte junctions [41].
Therefore, high levels of PDGFC might render tumors more
difficult to treat with anti-VEGF therapy by stabilizing vessels,
decreasing transvascular transport and minimizing their depen-
dence on VEGF for survival. In addition, there appears to be
communication between these pathways, as treatment with
VEGFR2 antibody increased PDGF-C production by the host cells.
The role of PDGF-C appears to vary significantly depending on
themicroenvironment.Arecentstudyoftumorassociated fibroblast
(TAF) involvement in subcutaneous tumor angiogenesis concluded
that TAFs produce PDGF-C to direct the process of endothelial cell
migration and angiogenesis, independent of VEGF [32]. On the
other hand, another group recently showed that PDGF-C secreted
by melanoma tumor cells helps recruit cancer associated fibroblasts,
which in turn, produce a tumor-promoting growth factor [42]. In
our study we found that PDGF-C produced by tumor cells can
recruit pericytes, stabilizing vessels and inhibiting DC101-induced
pruning. These seemingly divergent results are likely due to the lack
of fibroblasts in brain tumors. It is also possible that the discrepancy
is related to differences in local chemotactic gradients, which might
be overwhelmed by global expression of PDGF-C by the cancer
cells. These considerations underscore the need for a more
fundamental understanding of how this growth factor contributes
to tumor physiology in various growth sites.
Brain tumors have recently been the focus of trials with various
inhibitors of VEGF [43], which have had limited success– most
Figure 5. PDGF-C attenuates the response to VEGFR2 block-
ade. U87MG or U87-C tumor-bearing mice were treated with DC101
antibody (40 mg/kg) when their tumors reached 2 mm in diameter.
Intravenous injections of DC101 were performed on days 0, 3 and 6.
Vessels in the parental U87MG tumors are pruned in response to DC101
(fewer branch points). In contrast, U87-C tumors showed no response
(n=6).
doi:10.1371/journal.pone.0005123.g005
Figure 6. DC101 increases host PDGF-C expression. U87MG
tumor-bearing mice were treated with DC101 (40 mg/kg) when their
tumors reached 2 mm in diameter. Tumors were harvested and snap-
frozen at baseline (n=9), 2 days (n=8) and 8 days (n=5) after initiation
of treatment. Day 8 corresponds to the time of escape from DC101
treatment in this model[24]. Quantitative PCR was performed using
primers for mouse PDGF-C (forward primer: ACCACGAGTC-
CTTCGGTGTT, located at 529 bp; reverse primer: GCATTGTTGAG-
CAGGTCCAA, located at 566 bp). At day 8 DC101-treated tumors had
significantly more mouse PDGF-C compared to base line and to control,
baseline tumors (p,0.05) IgG-treated animals die before day 8.
doi:10.1371/journal.pone.0005123.g006
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investigate whether PDGF-C is involved in the resistance to anti-
VEGF therapy in the clinic, but this will only become possible as
patients enter clinical trials with up-front anti-VEGF treatment
with the possibility of resection at the time of recurrence, thereby
providing surgical specimens to address this important question.
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